# Wanbury share price today (Wanbury Ltd, NSE: WANBURY)

> Wanbury share price today: ₹192.41 at the NSE close on 4 November 2026, down 22.1% in a year. Wanbury (NSE: WANBURY) is worth ₹674 crore, trades at a P/E of 11.4 and has closed between ₹177.20 and ₹332.50 over the past 52 weeks. > Wanbury Ltd's P/E is near the low end of its own history, higher than only 19% of past readings, and its quarterly results are still getting worse. WANBURY · Pharma - API · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/wanbury-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹192.41 (−22.1% in a year)
- P/E: 11.4× (lower than 81% of the last 11 years)
- Revenue (Jun 2026): ₹166 Cr (+1.5% on a year ago)
- Profit (Jun 2026): ₹3.2 Cr (−76.0% on a year ago)
- Operating margin: 9.8% (−5.2 points on a year ago)
- ROCE: 31%, FY26
- ROIC: 23.0%, against a 12.0% cost of capital: +11.0 points

The main question: yearly earnings per share moved +103.1% while the share price moved −22.1%. ## What is the Wanbury share price today? Wanbury Ltd's share price was ₹192.41 at the close on 4 November 2026. It has been falling for 5 weeks. That is 21.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹177 and ₹333, and at that close it sat 10% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 14 weeks running. Over the last 11 years the share price moved +377% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Wanbury this quarter? 1. Profit fell in the June 2026 quarter Profit was ₹3 crore, -76% on a year earlier (₹13 crore), after 5 quarters of growth. 3. Lowest operating margin in 8 quarters Operating margin was 9.8% in the June 2026 quarter, against 15% a year earlier. ## What are Wanbury's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Wanbury reported revenue of ₹166 crore, up 1.5% from ₹163 crore a year earlier, and a profit of ₹3.24 crore, down 76.0% from ₹13.5 crore. ### Wanbury results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹166 crore | ₹163 crore | +1.5% |
| Profit | ₹3.24 crore | ₹13.5 crore | −76.0% |
| Earnings per share | ₹0.93 | ₹4.10 | −77.3% |
| Operating margin | 9.8% | 15.0% | −5.2 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Wanbury share price history? Wanbury closed at ₹192.41 on 4 November 2026, down 22.1% from ₹246.90 a year earlier (7 November 2025) and up 153.7% over five years. Its highest weekly close since February 2016 was ₹332.50 on 24 July 2026. ### Wanbury share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹189.75 | +1.4% |
| 1 month ago · 1 Oct 2026 | ₹199.00 | −3.3% |
| 6 months ago · 8 May 2026 | ₹254.00 | −24.2% |
| 1 year ago · 7 Nov 2025 | ₹246.90 | −22.1% |
| 3 years ago · 3 Nov 2023 | ₹93.50 | +105.8% |
| 5 years ago · 4 Nov 2021 | ₹75.85 | +153.7% |
| 10 years ago · 4 Nov 2016 | ₹45.60 | +322.0% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹40.30 | +377.4% |
| Highest weekly close since February 2016, also the 52-week high · 24 Jul 2026 | ₹332.50 | −42.1% |
| Lowest weekly close since February 2016 · 11 Oct 2019 | ₹11.32 | +1,599.7% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹177.20 | +8.6% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 26 February 2016 to 4 November 2026.)

## What is the latest news on Wanbury? 4 Nov 2026: Wanbury closed at ₹192.41, up 1.4% on the week and down 3.3% on the month. Results for April to June 2026: Revenue up 1.5% and profit down 76.0% on a year earlier. ### Earlier

- Our read, 31 May 2026: A legacy API manufacturer turning a financial corner through debt halving and Tanaku facility ramp-up, but the transition from generic volume to specialty margin is unproven at scale. ### Our read of the business

Debt reduced ~75% from peak ~700 Cr; borrowing cost down from 22.5% to 12.5%, finance cost relief is the dominant driver of profit recovery, not operational margin expansion.,Tanaku facility (Andhra Pradesh) achieved first commercial anaesthetic API shipment to Europe in October to December 2025; management goals ~100 Cr incremental revenue by FY27 from 4 new molecules/year.,operating margin expanded from 8% (FY24) to 13% (FY25) to 16% (9M FY26), margin recovery tied to both mix improvement and operating leverage on existing 386 KL reactor capacity. Latest quarter: Tanaku first commercial shipment, profit 1,194%, finance cost relief and API volume drive the number. (Our read after the latest results, written 31 May 2026.)

## What dividend does Wanbury pay? Wanbury has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Wanbury Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Wanbury management say on the latest results call? Wanbury's management made 0 promises we could check against what it later reported. (Our read after the latest results, written 31 May 2026.)

## What is the future of Wanbury? What is changing in the business? What is changing at Wanbury, from the latest results and calls: debt cost relief (ncd refinancing), tanaku facility, specialty api ramp and operating margin expansion via yield and solvent recovery. - Debt Cost Relief (NCD Refinancing). Borrowing cost cut from 22.5% to 12.5% from March 2025, finance cost fell from 10 Cr/quarter (October to December 2024) to 7 Cr/quarter (October to December 2025). ~75% debt reduction from 700 Cr peak. ⚠ estimate
- Tanaku Facility, Specialty API Ramp. Tanaku facility first commercial anaesthetic API shipment to Europe dispatched October to December 2025; goals ~100 Cr incremental revenue, 4 new molecules/year from FY27. ⚠ estimate
- Operating margin Expansion via Yield and Solvent Recovery. Operating margin 16% in October to December 2025 vs 11% in October to December 2024 (+500 basis points on a year earlier); driven by better yields, solvent recovery systems, and higher-margin SKU mix. ⚠ estimate
- Regulated Market Expansion (USFDA / ANVISA / MFDS-Korea). 6th USFDA inspection at Patalganga passed with zero 483 observations; ANVISA Brazil GMP cert for Tanaku; Korea MFDS Patalganga clearance April 2026. Three major regulators clean simultaneously. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 31 May 2026.)

## What could change the Wanbury story? What are the risks? First commercial shipment dispatched October to December 2025 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch. ### The main risks

- Tanaku Revenue Ramp Slippage: First commercial shipment dispatched October to December 2025 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch. ✓ fact
- Finance Cost Floor, profit Growth Decelerates: Finance cost savings are the dominant FY26 profit driver. At 7 Cr/quarter, interest expense is near floor. Future profit growth needs genuine operating leverage. ✓ fact
- Generic API Pricing Pressure: Antidiabetic molecules (Metformin: 11% global share; Sertraline: 30% global share) are high-volume generics with inherent pricing pressure from Chinese manufacturers. ✓ fact
- Low Promoter Conviction: Promoter stake flat at 39.6-39.8% over 6 quarters despite a clear turnaround. ✓ fact

(Our read after the latest results, written 31 May 2026.)

## What to watch in Wanbury's next results? When Wanbury reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: Tanaku revenue contribution in April to June 2026 concall; second customer off-take announcement. | What to check | Why |
| --- | --- |
| Tanaku revenue contribution in April to June 2026 concall; second customer off-take announcement. | Tanaku Revenue Ramp Slippage |
| April to June 2026 profit on a year earlier growth vs April to June 2025 profit of 13 Cr; operating profit growth rate decoupled from profit. | Finance Cost Floor, profit Growth Decelerates |
| API realization per kg for Metformin and Sertraline in Q1/July to September 2026. | Generic API Pricing Pressure |
| Any SAST disclosure of promoter stake-building above 2% threshold. | Low Promoter Conviction |
| BV per share trajectory in annual results; ROE should normalize toward 30-40% range as book rebuilds. | Thin Equity Book, ROE Optically High |

## Which stock lists is Wanbury on? Wanbury is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 673.1960255800433](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Wanbury profitable? Wanbury Ltd earned ₹3.2 Cr of net profit in the Jun 2026 quarter, −76.0% on the same quarter a year earlier. Full-year FY26 profit was ₹66.0 Cr. That is 2.0% of the quarter's revenue. The same quarter a year earlier earned ₹13.5 Cr. For the full year, FY26 profit was ₹66.0 Cr (+112.9% on the year before). Why profit moved: revenue changed +1.5% on a year earlier and the margin moved −5.2 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +303.0% and revenue +4.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Wanbury make, and is it growing? Wanbury Ltd reported ₹166 Cr of revenue in the Jun 2026 quarter, +1.5% on the same quarter a year earlier. Over 10 years it has grown 4.5% a year on average. The last full year, FY26, came in at ₹650 Cr. The last four reported quarters add to ₹653 Cr. Why this happened. The formulations business, representing 12% of FY25 revenue, turned EBITDA positive in 9M FY26. Strategy involves transitioning from acute to specialty/chronic segments and geographical expansion into new markets. Field force build-out is planned for scale-up in FY27. The risk remains that this is a small segment (70 Cr FY25) and recurring profitability is not yet demonstrated across a full year. FY26 revenue was ₹650 Cr, +8.3% on the year before. Recent pace: the last four quarters grew +4.5% on average, against 4.5% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.6%, against +7.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +30.0%, against +44.5% a year (rolling over). ## How much of every ₹100 of sales does Wanbury keep? Wanbury Ltd's operating margin was 9.8% in the Jun 2026 quarter, 5.2 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −18.0% and 16.0%. The latest quarter is within that range. Why this happened. Tanaku facility in Andhra Pradesh cleared ANVISA (Brazil) GMP audit with zero observations. First commercial shipment of high-potent anaesthetic API to a European customer dispatched in Q3 FY26. Management goals ~100 Cr revenue contribution and full commercial production by FY27. The product portfolio covers antitussive, anticoagulant, anaesthetic, and antidepressant molecules, regulated-market focused. Revenue is nascent and the milestone tracking gate is whether Tanaku exceeds 50 Cr revenue in FY27. Why the margin moved: operating margin changed −5.2 percentage points on the year while gross margin changed −1.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Wanbury's profit turning into cash? Over the last 3 years, 50% of Wanbury Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹32.0 Cr of operating cash against ₹66.0 Cr of profit. After ₹62.0 Cr of spending on assets, free cash was −₹30.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 50% of profit came in as cash: the cash cycle got 153 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 153 days longer. The next section looks at where the cash is stuck. ## Where does Wanbury's cash go? Wanbury Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 6 days in FY26, up from −147 days in FY21. It spent ₹125 Cr on assets over the last 3 years. Customers take 80 days to pay, and stock sits for 67 days on average. At FY26 sales of ₹650 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹11.0 Cr is tied up in the business at any time. FY26: customers took 80 days to pay and stock sat for 67 days, about 2.2 months of sales sitting as stock, for a full cycle of 6 days, longer than FY21's −147. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 67 days. Customers pay about 80 days after that. Suppliers are paid at 142 days. Together that makes the 6-day cycle. Spending on assets: ₹125 Cr over the last 3 years, against ₹40.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹25.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Wanbury's P/E ratio, and how does it compare with its own history? Wanbury Ltd's P/E is 11.4×, near the low end of its own history: it has been lower only 19% of the time. Its usual P/E (the middle reading) is 20.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹16.01. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +103.1% while the price moved −22.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 10 years the price moved +15.5% a year; about −6.6% a year came from earnings growth and about +22.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Wanbury share price assume? Worked out from its price on 27 August 2026, Wanbury Ltd's share price assumed profit growth of about 7.7% a year. Today its P/E is 11.4×, lower than 81% of its own last 11 years. This is a one-day reading, taken on 27 August 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Wanbury business getting better or worse? Wanbury Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +827.8% at its peak to +30.0%, but the business is still expanding, with ROCE falling at 29.2%. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the Wanbury story, and has it been checked? Wanbury Ltd's story is not scored yet against the checks our research set on 31 May 2026. Where it sits in its own cycle: Not stated in the research file. Still open: First commercial shipment dispatched Q3 FY26 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch. European customer off-take timeline unconfirmed. Our read, 31 May 2026. A legacy API manufacturer turning a financial corner through debt halving and Tanaku facility ramp-up, but the transition from generic volume to specialty margin is unproven at scale. What is proven. A legacy API manufacturer turning a financial corner through debt halving and Tanaku facility ramp-up, but the transition from generic volume to specialty margin is unproven at scale. What is not proven yet. First commercial shipment dispatched Q3 FY26 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch. European customer off-take timeline unconfirmed. The test written in advance. Tanaku Revenue Ramp Slippage. Measured by: Tanaku Revenue Ramp Slippage Tanaku revenue contribution in Q1 FY27 concall; second customer off-take announcement by the next result. The test written in advance. Finance Cost Floor, PAT Growth Decelerates. Measured by: Finance Cost Floor, PAT Growth Decelerates Q1 FY27 PAT YoY growth vs Q1 FY26 PAT of 13 Cr; operating profit growth rate decoupled from PAT by the next result. The test written in advance. Generic API Pricing Pressure. Measured by: Generic API Pricing Pressure API realization per kg for Metformin and Sertraline in Q1/Q2 FY27 by the next result. What the company does. Debt reduced ~75% from peak ~700 Cr; borrowing cost down from 22.5% to 12.5%, finance cost relief is the dominant driver of PAT recovery, not operational margin expansion. Tanaku facility (Andhra Pradesh) achieved first commercial anaesthetic API shipment to Europe in Q3 FY26; management goals ~100 Cr incremental revenue by FY27 from 4 new molecules/year. OPM expanded from 8% (FY24) to 13% (FY25) to 16% (9M FY26), margin recovery tied to both mix improvement and operating leverage on existing 386 KL reactor capacity. Lever 5 · Regulatory approval: building. Borrowing cost cut from 22.5% to 12.5% from March 2025, finance cost fell from 10 Cr/quarter (Q3 FY25) to 7 Cr/quarter (Q3 FY26). ~75% debt reduction from 700 Cr peak. What proves it keeps working: Debt Cost Relief (NCD Refinancing). It stops working if Tanaku revenue contribution in Q1 FY27 concall; second customer off-take announcement. Lever 1 · Operating leverage: building. Tanaku facility first commercial anaesthetic API shipment to Europe dispatched Q3 FY26; goals ~100 Cr incremental revenue, 4 new molecules/year from FY27. What proves it keeps working: Tanaku Facility, Specialty API Ramp. It stops working if Tanaku revenue contribution in Q1 FY27 concall; second customer off-take announcement. Lever 2 · Value-added mix: building. OPM 16% in Q3 FY26 vs 11% in Q3 FY25 (+500 bps YoY); driven by better yields, solvent recovery systems, and higher-margin SKU mix. What proves it keeps working: OPM Expansion via Yield and Solvent Recovery. It stops working if Tanaku revenue contribution in Q1 FY27 concall; second customer off-take announcement. Lever 9 · Buyback: building. 6th USFDA inspection at Patalganga passed with zero 483 observations; ANVISA Brazil GMP cert for Tanaku; Korea MFDS Patalganga clearance April 2026. Three major regulators clean simultaneously. What proves it keeps working: Regulated Market Expansion (USFDA / ANVISA / MFDS-Korea). It stops working if Tanaku revenue contribution in Q1 FY27 concall; second customer off-take announcement. Sources: our stock research file (31 May 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes. ## What is Wanbury management's track record? Turnaround real but FY26 profit is finance-cost-relief-led; operating-leverage proof pending. ### Regulatory and governance record

FY26 secretarial compliance, one minor violation (late Sep-2025 shareholding pattern filing); no SEBI/CBI/ED action surfaced. 0% Promoter shares pledged

Sources:

- [trendlyne.com](https://trendlyne.com/fundamentals/financials/1510/WANBURY/wanbury-ltd)
- [scanx.trade](https://scanx.trade/stock-market-news/companies/wanbury-limited-receives-secretarial-compliance-report-for-fy26-with-minor-violation/38617578)
- [scanx.trade](https://scanx.trade/stock-market-news/companies/wanbury-promoter-group-s-40-65-equity-share-pledge-released-borrowing-costs-to-fall-below-10-annually-from-july-1-2026/43921338)

(Checked 30 June 2026.)

## How much does Wanbury earn on its capital? Wanbury Ltd earned a ROCE of 31% in FY26. That is up from a low of −1% in FY18. Its return on capital used (ROIC) is 11.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 10.2% net margin and 1.25× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 10.2% net margin × 1.25× asset turnover × 3.57× leverage (assets divided by equity) ≈ 45.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 23.0% − 12.0% = +11.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 23.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 30.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Wanbury have too much debt? Wanbury Ltd has total debt of ₹224 Cr against shareholder equity of ₹144 Cr as of Jun 2026, so its debt is 1.56× its equity. Year by year, that ratio went from 27.00 in FY22 to 1.56 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Wanbury shareholding pattern? Promoters raised their stake in Wanbury Ltd by 3.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 43.0% of the company. Foreign institutions moved −0.3 points over the same period, to 0.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. Wanbury's two USFDA-approved API facilities (Patalganga + Tanaku) have now added ANVISA Brazil and Korea MFDS certifications. Sertraline Form II and Metformin DC Grade received ANVISA approval in March 2026, these are existing high-volume molecules gaining new market access. The regulatory track record de-risks the Tanaku ramp and supports European customer acquisition. Over the last two years: Promoters: +3.2 points over 8 quarters, to 43.0%; Foreign institutions: −0.3 points over 8 quarters, to 0.7%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. Why the owners changed: promoters drove it (+3.2 points). They raised their stake step by step. ## How far is Wanbury from balance-sheet trouble? For Wanbury Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. Why this happened. The primary driver of PAT recovery in FY26 is financial engineering rather than new revenue. Debt reduced ~75% from peak ~700 Cr and refinanced NCDs at 12.5% vs prior 22.5%. Interest expense savings of ~3 Cr per quarter translate directly to PAT. This driver is mature, further step-down in finance cost is limited. The next leg of PAT growth must come from operations. ## How does Wanbury rank in its industry? 55.3 out of 100, rank 6 of 14 in Pharma - API, with 81% of the evidence available. Wanbury Ltd scores 55.3 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 6. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 12 + 16.6 + 19.2 + 7.5 = 55.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Wanbury compared with? Wanbury ranks 6 of 14 Pharma - API companies on the 4-Factor Sector Score, with 55.3 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. Wanbury Ltd this page WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Wanbury in size? Wanbury is the 14th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Beta Drugs, Jagsonpal Pharmaceuticals, Fermenta Biotech, Kopran, Anuh Pharma and Themis Medicare. It is the smallest. ### Pharma - API companies close in size

1. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,000 crore
2. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,427 crore
3. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) ₹1,229 crore
4. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) ₹1,155 crore
5. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ₹875 crore
6. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) ₹873 crore
7. Wanbury Ltd ₹662 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [VLS Finance Ltd](https://www.sectoralpha.in/stocks/vls-finance-ltd) ₹666 crore · Finance & Investments - Others
2. [Hexagon Nutrition Ltd](https://www.sectoralpha.in/stocks/hexagon-nutrition-ltd) ₹665 crore · Food - Processing - Others
3. Wanbury Ltd ₹662 crore
4. [R M Drip & Sprinklers Systems Ltd](https://www.sectoralpha.in/stocks/r-m-drip-sprinklers-systems-ltd) ₹661 crore · Plastics - Drip Irrigation
5. [Parth Electricals & Engineering Ltd](https://www.sectoralpha.in/stocks/parth-electricals-engineering-ltd) ₹659 crore · Electric Equipment - General

## What else do people ask about Wanbury? ### What is Wanbury's share price today? Wanbury Ltd's share price is ₹192.41, −22.1% over the past year. The whole company is worth ₹674 Cr on the market. In the last 52 weeks it traded between ₹177 to ₹333; today it is 10% of the way up from the low, 21.6% below its 200-day average (as of 4 November 2026). ### What were Wanbury's latest quarterly results? Wanbury Ltd reported revenue of ₹166 Cr and net profit of ₹3.2 Cr for the Jun 2026 quarter. Revenue rose 1.5% and profit fell 76.0% compared with a year earlier. Earnings per share were ₹0.93. The operating margin was 9.8%, 5.2 percentage points lower than a year earlier (as of 4 November 2026). ### What is Wanbury's market cap? Wanbury Ltd's market capitalisation is ₹674 Cr at a share price of ₹192.41. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Wanbury performing? Wanbury Ltd's share price has been falling for 5 weeks. In its latest quarter, revenue rose 1.5% and profit fell 76.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 14 weeks running (as of 4 November 2026). ### Will Wanbury's share price go up? This page does not forecast Wanbury Ltd's share price. What it shows instead: the share price is ₹192.41, and it has been falling for 5 weeks. Its P/E of 11.4× is higher than 19% of its own last 11 years (as of 4 November 2026). ### Who owns Wanbury? Promoters own 43.0% of Wanbury Ltd, foreign institutions 0.7%, domestic institutions 0.0% and the public 56.3% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 3.2 percentage points over 8 quarters (as of 4 November 2026). ### Does Wanbury have too much debt? Yes, Wanbury Ltd has a lot of debt: its debt is 1.56× its equity, and its operating profit is 4 times its interest bill. FY26 borrowings were ₹226 Cr against equity of ₹145 Cr. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is Wanbury in its business cycle? Wanbury Ltd's FY26 operating margin was 16.0%, against a 13-year range of −18.0% to 16.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 9.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Wanbury story? The main question: yearly earnings per share moved +103.1% while the share price moved −22.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Wanbury a stock worth studying right now? What the numbers show: Wanbury Ltd's P/E is near the low end of its own history, higher than only 19% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Wanbury share price forecast for 2026? What is changing at Wanbury, from the latest results and calls: debt cost relief (ncd refinancing), tanaku facility, specialty api ramp and operating margin expansion via yield and solvent recovery. What would change the story: First commercial shipment dispatched October to December 2025 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch. ### Where does this page get Wanbury's management information? From Wanbury's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.